Cisplatin
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
The Atlas of Anti-Cancer Drug Nephrotoxicity
A citation-grounded onconephrology reference that connects 292 agents — chemotherapy, targeted therapy, immunotherapy — by the toxic ties they share, from cisplatin to the 2026 frontier and MGRS.
292 agents · 14 signatures · 1,642 citations · updated November 2026
Every claim tied to a primary source.
Search all 292 agents, 14 injury signatures, and every profile citation. Opens the command palette —⌘Kanywhere on the site.
Search the atlasStart from the patient: enter the regimen and the kidney picture, and rank which agent most plausibly explains it — with the evidence behind each call.
Open the culprit consoleThe data behind the atlas: phenotype similarity, nephron anatomy, how the evidence base grew, and FAERS reporting signals.
Open Insights§ 00Start here
Short, ordered journeys matched to why you came.
§ 01The toxic ties
Every agent is wired to each injury it can cause. Chemically unrelated drugs that share a signature pull toward the same hub — drag a node, or open the full network.
The vocabulary · filter the atlas by injury signature
§ 02Why it matters
Onconephrology sits where two epidemics meet. Every figure below links to its primary source.
| Incidence | Clinical finding | Source |
|---|---|---|
| 27% | of cancer patients develop AKI within 5 years 5-year cumulative incidence of acute kidney injury after a cancer diagnosis (1-year: 17.5%). Christiansen et al., Eur J Intern Med 2011 · PMID 21767759 | Christiansen et al., Eur J Intern Med 2011 · PMID 21767759 |
| 53% | carry hidden kidney impairment at diagnosis Abnormal renal function by aMDRD in solid-tumor patients, yet only 7.2% of the cohort had an elevated serum creatinine (IRMA study). Launay-Vacher et al., Cancer 2007 · PMID 17634949 | Launay-Vacher et al., Cancer 2007 · PMID 17634949 |
| 4.7× | higher odds of death with in-hospital AKI Cancer inpatients who develop AKI face nearly fivefold mortality, +100% length of stay. Salahudeen et al., CJASN 2013 · PMID 23243268 | Salahudeen et al., CJASN 2013 · PMID 23243268 |
| ~1 in 3 | adults develop acute kidney injury after cisplatin 31.5% of 821 adults had AKI (a creatinine rise of more than 25%) within 30 days of the first cycle, in a cohort of patients who survived at least 5 years. Latcha et al., CJASN 2016 · PMID 27073199 | Latcha et al., CJASN 2016 · PMID 27073199 |
Onconephrology. Onconephrology is the nephrology subspecialty at the bidirectional intersection of cancer and the kidney — the nephrotoxicity of anticancer therapy, AKI and CKD in cancer patients, electrolyte disorders, tumor lysis syndrome, paraneoplastic glomerular disease and drug dosing in renal impairment. The field coalesced around 2010–2014, with the ASN onconephrology forum established in 2011. Read the field primer
§ 03Deep profiles
All 292 agents carry full, citation-grounded profiles — mechanism, incidence, prevention, management, dose adjustment, clinical pearls, and a real-world FAERS signal where the data exists.
Platinol · Platinum agent
Proximal tubular ATN + magnesium wasting; the archetype.
Gemzar · Nucleoside analog
Dose-cumulative thrombotic microangiopathy.
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
§ 04Deep dives
Starve a tumor of its blood supply and you also cut the survival signal podocytes whisper to the glomerular endothelium next door — the capillary tuft answers with thrombi, protein spilling into the urine, and a blood pressure that will not come down.
The drug that cures testicular cancer poisons its own portal of entry — pumped into the kidney's S3 tubule by OCT2, cisplatin necroses the proximal tubule and, downstream, silences the distal magnesium channel, leaving patients wasting magnesium long after the last dose.
By occupying the EGF receptor that keeps the TRPM6 channel trafficked to the apical membrane of the distal tubule, cetuximab and panitumumab convert the kidney into a magnesium sieve — an on-target, designed-in toxicity that deepens the longer the drug keeps working.
Mesna guards the bladder, but nothing guards the proximal tubule — ifosfamide's chloroacetaldehyde metabolite is made inside the tubular cell itself, draining its energy and its reabsorptive machinery until phosphate, glucose, bicarbonate, and amino acids leak into the urine.
§ 05Beyond the core atlas
Trace each drug to the segment it injures, glomerulus to collecting duct.
Emerging real-world signals and graded theoretical toxicities for the newest agents.
When the antibody itself is nephrotoxic: nine lesions, workup, clone-directed therapy.
Updates to the atlas
New agents are discovered from the PubMed literature and reviewed before they appear, with an optional email notice whenever the atlas is updated.
Built on deep research across PubMed and current nephrology literature. Educational reference — not medical advice.